ArticleMicrobial cell factories2016
Recombinant production of medium- to large-sized peptides in Escherichia coli using a cleavable self-aggregating tag.
Article in Microbial cell factories, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The effect of monomers number in peptides on Escherichia coli strain productivity and inclusion bodies-associated target protein accumulation.Folia microbiologica · 2026Article
- Nanoparticles and Nanomaterials: A Review from the Standpoint of Pharmacy and Medicine.Pharmaceutics · 2025Review
- Conditional Split Inteins: Adaptable Tools for Programming Protein Functions.International journal of molecular sciences · 2025Review
- A miniature low-immunogenic platform for the biosynthesis of self-assembling protein nanoparticles.Nanotheranostics · 2025Article
- Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review.International journal of medical sciences · 2025Review
- Unveiling the Pain Relief Potential: Harnessing Analgesic Peptides from Animal Venoms.Pharmaceutics · 2023Review
- A novel protein purification scheme based on salt inducible self-assembling peptides.Microbial cell factories · 2023Article
- Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells.Advanced pharmaceutical bulletin · 2023Article
- A toolkit for recombinant production of seven human EGF family growth factors in active conformation.Scientific reports · 2022Article
- Title: insoluble proteins catch heterologous soluble proteins into inclusion bodies by intermolecular interaction of aggregating peptides.Microbial cell factories · 2021Article
- Effective production of human growth factors in Escherichia coli by fusing with small protein 6HFh8.Microbial cell factories · 2021Article
- Production of a toxic polypeptide as a fusion inside GroEL cavity.Scientific reports · 2020Article
- Catalytically-active inclusion bodies for biotechnology-general concepts, optimization, and application.Applied microbiology and biotechnology · 2020Review
- Designing and overproducing a tandem epitope of gp350/220 that shows a potential to become an EBV vaccine.Heliyon · 2018Article
- A novel secretion and online-cleavage strategy for production of cecropin A in Escherichia coli.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPeptides have recently become attractive for therapeutic applications. However, efficient production of medium- to large-sized peptides (30-100 amino acids [aa]) remains challenging both by recombinant and chemical synthesis. We previously reported the formation of active enzyme aggregates in Escherichia coli cells induced by the short β-structured peptide ELK16 (LELELKLKLELELKLK) and developed a streamlined protein expression and purification approach. In this approach, a cleavable self-aggregating tag (cSAT) consisting of an intein molecule and ELK16 was used to release the recombinant peptides with reasonable purity from active aggregates.
resultsIn this work, we extended the cSAT approach to a generalized expression and purification solution for a set of medium- to large-sized peptides with important therapeutic uses, including human glucagon-like peptide 1 (31 aa), B-type natriuretic peptide (32 aa), exendin 4 (39 aa), chemokine (C-C motif) ligand 5 (also known as RANTES, 66 aa), stromal cell-derived factor 1α (67 aa), insulin-like growth factor 1 (70 aa), and leptin (146 aa). After intein-mediated cleavage, the soluble peptides were released directly into the supernatant while insoluble peptides could be refolded and purified by reverse phase high-performance liquid chromatography. Additionally, an N-terminal thioredoxin tag was added upstream of the target peptides, which can be removed by enterokinase cleavage, generating native N-terminus for target peptides. Final yields of the peptides ranged from 0.1 to 1.8 μg/mg wet cell weight at laboratory scale.
conclusionsThe approach described in this study provides a fast and efficient route to express and purify peptides that are difficult or expensive to produce by chemical synthesis or by ordinary recombinant methods. It is particularly well suited for large peptides, peptides likely to be degraded, and peptides that have toxic effects on the host. It can greatly reduce the cost and time of downstream processing, and thus may be useful for both industrial manufacture and laboratory applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.